Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Summary
The novel treatment approach, termed sonoreperfusion (SRP), utilizes ultrasound-targeted microbubble cavitation (UTMC) to dissolve obstructive microthrombi in the microvasculature.Study Highlights: In this groundbreaking study, the research team aimed to determine the therapeutic efficacy of FTPSMBs in achieving successful reperfusion of MVO. Unlike standard-sized lipid microbubbles, FTPSMBs are smaller in size and specifically designed for enhanced thrombus dissolution.Key Findings:- In vitro binding affinity assays demonstrated increased fibrin binding peptide (FBP) affinity for the fibrin clots compared with control peptide.- In an in vitro model of MVO, FTPSMBs exhibited higher binding affinity with microthrombi compared to other formulations.- In a hindlimb rat model, UTMC with FTPSMBs yielded the greatest recovery of blood volume and flow rate following MVO compared to all other treatment groups.Implications and Future Directions: The studys findings suggest that SRP with FTPSMBs achieves more rapid and complete reperfusion of MVO compared to other formulations. John J. Pacella, MD, MS, Corresponding Author, University of Pittsburgh, says: "We are excited about the promising results of our study, which highlight the potential of Fibrin-Targeted Phase Shift Microbubbles in revolutionizing the treatment of Microvascular Obstruction. MVT has developed a new, patented microbubble that serves as a platform for development of agents for molecular imaging and image-guided therapy.For more information or media inquiries, please contact:Company contact:Microvascular Therapeutics, IncDr Evan C Unger, Chairman BOD (e.unger@mvtpharma.com)Emmanuelle J Meuillet, COO/CSO e.meuillet@mvtpharma.comInvestor Contact:Bryan UngerT: 520.907.3537E: b.unger@mvtpharma.comForward-looking statement Press Release Distribution Terms of Use or results may differ substantially as a result of risks and uncertainties facing us. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.